PURPOSE: The main objective of this investigation was to explore the cytotoxic structure-activity relationships of gamma-substituted gamma-aryloxymethyl-alpha-methylene-gamma-butyrolactones against cancer cells. METHODS: The target compounds were synthesized in two steps commencing with aryl-OH which was treated with a bromomethyl ketone followed by the Reformatsky-type condensation. RESULTS: Seven types of alpha-methylene-gamma-butyrolactones were evaluated in vitro against 60 human cancer cell lines derived from nine cancer cell types. The average values of log GI50 indicated that for the aryl portion, potencies of these alpha-methylene-gamma-butyrolactones are in a decreasing order of quinolin-2(1H)-one (or 2-hydroxyquinoline, 21, -5.89) > quinoline (19, -5.79) > 2-methylquinoline (20, -5.69) >8-hydroxyquinoline (17,-5.64) > 2-naphthalene (16, -5.59) > benzene (15, -4.90). The same order was obtained for both log TGI and log LC50. However, for the gamma-substituent, the potencies are in a decreasing order of biphenyl (16f-21f) > phenyl and 4-substituted phenyl (16b-e-21b-e) > methyl (16a-21a). CONCLUSIONS: Unlike cardiovascular activities of alpha-methylene-gamma-butyrolactones in which a gamma-methyl substituent is necessary for vasorelaxing effect while a phenyl or a halogen-substituted phenyl is prefer for the antiplatelet activities, a gamma-biphenyl substituent proved to be the best for their cytotoxicities against various cancer cell lines tested.
PURPOSE: The main objective of this investigation was to explore the cytotoxic structure-activity relationships of gamma-substituted gamma-aryloxymethyl-alpha-methylene-gamma-butyrolactones against cancer cells. METHODS: The target compounds were synthesized in two steps commencing with aryl-OH which was treated with a bromomethyl ketone followed by the Reformatsky-type condensation. RESULTS: Seven types of alpha-methylene-gamma-butyrolactones were evaluated in vitro against 60 humancancer cell lines derived from nine cancer cell types. The average values of log GI50 indicated that for the aryl portion, potencies of these alpha-methylene-gamma-butyrolactones are in a decreasing order of quinolin-2(1H)-one (or 2-hydroxyquinoline, 21, -5.89) > quinoline (19, -5.79) > 2-methylquinoline (20, -5.69) >8-hydroxyquinoline (17,-5.64) > 2-naphthalene (16, -5.59) > benzene (15, -4.90). The same order was obtained for both log TGI and log LC50. However, for the gamma-substituent, the potencies are in a decreasing order of biphenyl (16f-21f) > phenyl and 4-substituted phenyl (16b-e-21b-e) > methyl (16a-21a). CONCLUSIONS: Unlike cardiovascular activities of alpha-methylene-gamma-butyrolactones in which a gamma-methyl substituent is necessary for vasorelaxing effect while a phenyl or a halogen-substituted phenyl is prefer for the antiplatelet activities, a gamma-biphenyl substituent proved to be the best for their cytotoxicities against various cancer cell lines tested.
Authors: A Monks; D Scudiero; P Skehan; R Shoemaker; K Paull; D Vistica; C Hose; J Langley; P Cronise; A Vaigro-Wolff Journal: J Natl Cancer Inst Date: 1991-06-05 Impact factor: 13.506
Authors: K H Lee; I H Hall; E C Mar; C O Starnes; S A ElGebaly; T G Waddell; R I HADGRAFT; C G Ruffner; I Weidner Journal: Science Date: 1977-04-29 Impact factor: 47.728
Authors: Lukas K Filak; Gerhard Mühlgassner; Michael A Jakupec; Petra Heffeter; Walter Berger; Vladimir B Arion; Bernhard K Keppler Journal: J Biol Inorg Chem Date: 2010-04-06 Impact factor: 3.358
Authors: Letícia Martins Dos Reis Lage; José Mário Barichello; Daniela Pagliara Lage; Débora Vasconcelos Costa Mendonça; Ana Maria Ravena Severino Carvalho; Marcella Rezende Rodrigues; Daniel Menezes-Souza; Bruno Mendes Roatt; Ricardo José Alves; Carlos Alberto Pereira Tavares; Eduardo Antonio Ferraz Coelho; Mariana Costa Duarte Journal: Parasitol Res Date: 2016-07-01 Impact factor: 2.289
Authors: Sara M Mostafa; Ashraf A Aly; Alaa A Hassan; Esraa M Osman; Stefan Bräse; Martin Nieger; Mahmoud A A Ibrahim; Asmaa H Mohamed Journal: Molecules Date: 2022-03-25 Impact factor: 4.411